In Vitro and In Vivo Diagnostic Substances - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the In industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

In Vitro and In Vivo Diagnostic Substances - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - In Vitro and In Vivo Diagnostic Substances
Corporate Insider Buy Sell Ratio (Insider Count) - In Vitro and In Vivo Diagnostic Substances
In Vitro and In Vivo Diagnostic Substances - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2026-03-13 MYGN / Myriad Genetics, Inc. 4 Verratti Mark F - Taxes D 4.66 -9,164
2026-03-13 MYGN / Myriad Genetics, Inc. 4 Fox Jennifer Lynne F - Taxes D 4.66 -5,995
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Muzzey Dale A - Award D 173,196
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Fox Jennifer Lynne A - Award D 195,876
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Solaiman Shereen A - Award D 173,196
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Raha Samraat S. A - Award D 618,557
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Wheeler Benjamin Richard A - Award D 206,186
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Verratti Mark A - Award D 247,423
2026-03-12 MYGN / Myriad Genetics, Inc. 4 Donnelly Brian J A - Award D 226,804
2026-03-09 MYGN / Myriad Genetics, Inc. 4 Raha Samraat S. P - Purchase D 4.9961 40,000
2026-03-06 TKNO / Alpha Teknova, Inc. 4 Lowell Matthew P - Purchase D 2.1904 40,000
2026-03-06 TKNO / Alpha Teknova, Inc. 4 Gunstream Stephen P - Purchase D 2.1462 26,000
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Marshall Robert J. Jr. F - Taxes D 76.31 -1,182
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Brown Kimberly F - Taxes D 76.31 -133
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Morgan Amanda Michelle F - Taxes D 76.31 -595
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Niedzwiecki Daniel F - Taxes D 76.31 -1,283
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Niedzwiecki Daniel A - Award D 36,692
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Brown Kimberly A - Award D 6,158
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Dinkelborg Ludger A - Award D 20,966
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Marshall Robert J. Jr. A - Award D 38,002
2026-03-05 LNTH / Lantheus Holdings, Inc. 4 Morgan Amanda Michelle A - Award D 26,208
2026-03-03 IDXX / IDEXX Laboratories, Inc. 4 Hunt Nimrata S - Sale D 634.5718 -1,758
2026-03-03 IDXX / IDEXX Laboratories, Inc. 4 Underberg Sharon E. M - Exercise D 505.53 197
2026-03-02 NTLA / Intellia Therapeutics, Inc. 4 Clark Eliana S - Sale D 13.78 -607
2026-03-02 NTLA / Intellia Therapeutics, Inc. 4 BASTA JAMES S - Sale D 13.78 -1,211
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Marshall Robert J. Jr. F - Taxes D 76.3 -10,652
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Heino Mary Anne F - Taxes D 76.30 -41,916
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Morgan Amanda Michelle F - Taxes D 76.30 -3,336
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Niedzwiecki Daniel F - Taxes D 76.30 -8,259
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Niedzwiecki Daniel A - Award D 5,169
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Heino Mary Anne A - Award D 32,105
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Marshall Robert J. Jr. A - Award D 8,491
2026-03-02 LNTH / Lantheus Holdings, Inc. 4 Morgan Amanda Michelle A - Award D 2,782
2026-03-01 MYGN / Myriad Genetics, Inc. 4 Solaiman Shereen F - Taxes D 4.61 -1,675
2026-03-01 VNRX / VolitionRx Limited 4 Forterre Gael F - Taxes D 0.213 -2,283
2026-03-01 VNRX / VolitionRx Limited 4 Rootsaert Rodney Gerard F - Taxes D 0.213 -3,321
2026-03-01 VNRX / VolitionRx Limited 4 Plummer Nicholas F - Taxes D 0.213 -5,867
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 Clark Eliana A - Award D 7,353
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 Schultes Birgit C A - Award D 39,200
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 Lebwohl David A - Award D 9,943
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 Dulac Edward J III A - Award D 61,280
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 BASTA JAMES A - Award D 46,080
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 LEONARD JOHN M. A - Award D 156,400
2026-03-01 NTLA / Intellia Therapeutics, Inc. 4 Dube Michael P A - Award D 17,250
2026-02-27 MYGN / Myriad Genetics, Inc. 4 Phanstiel S. Louise P - Purchase D 4.661 48,000
2026-02-27 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY M - Exercise D 505.53 197
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 659.7495 -2,859
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 662.1567 -1,000
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 653.6763 -1,171
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 Hunt Nimrata S - Sale D 661.5413 -2,693
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)